Friday, March 15, 2013

Nippon Kayaku and Teva receive approval for biosimilar G-CSF (fligrastim) in Japan

Teva Pharmaceutical and Nippon Kayaku have received marketing approval of biosimilars (recombinant) formulation filgrastim (G-CSF) recombinant human granulocyte colony-stimulating factor gene that has been jointly developed.  This is the second approval for biosimilar fligrastim in Japan and the the first biosimilar that will be  co-marketed by Nippon Kayaku Co., Ltd. and Teva Pharmaceuticals in Japan. Sandoz was the first company to get an approval for biosimilar filgrastim in Japan.

As with the original drug, acts on neutrophil precursor cells, to promote the proliferation, differentiation and its biosimilar filgrastim of (recombinant) promotes the release of neutrophils from the bone marrow, enhances its function. In the field of cancer treatment, it is used for chemotherapy-induced neutropenia mainly cancer.







Enter your email address:


Delivered by FeedBurner